BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:NovoLog (insulin aspart) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of NovoLog (insulin aspart)\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06532461-316@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:NovoLog (insulin aspart): Phase na readout est. (NCT06532461)
DESCRIPTION:NovoLog (insulin aspart)\, phase na\, Type 1 Diabetes.\nStudy: 
 A Trial of Three- and Seven-days Insulin Infusions Set\nEstimated primary 
 completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/insulin-aspart#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06532461
URL:https://assetmemo.bio/drug/insulin-aspart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07918898-316@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:NovoLog (insulin aspart): Phase 1 readout est. (NCT07918898)
DESCRIPTION:NovoLog (insulin aspart)\, phase 1.\nStudy: Comparison of Pharm
 acokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injecti
 on With Separately Injected\, Simultaneous Doses of GZR33 Injection and In
 sulin Aspart\nEstimated primary completion: 2 February 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/insulin-aspart#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07918898
URL:https://assetmemo.bio/drug/insulin-aspart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07875803-316@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:NovoLog (insulin aspart): Phase na readout est. (NCT07875803)
DESCRIPTION:NovoLog (insulin aspart)\, phase na.\nStudy: Comparison of the 
 Pharmacokinetic (PK) and Pharmacodynamic (PD) Biosimilarity of Insulin Asp
 art 30 Injections After Single-Dose Subcutaneous Administration to Healthy
  Volunteers\nEstimated primary completion: 28 February 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/insulin-aspart#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07875803
URL:https://assetmemo.bio/drug/insulin-aspart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07652528-316@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:NovoLog (insulin aspart): Phase na readout est. (NCT07652528)
DESCRIPTION:NovoLog (insulin aspart)\, phase na\, Type 2 Diabetes.\nStudy: 
 CGM-guided Patch Pump vs Basal-Bolus Injection for Steroid-Induced Hypergl
 ycemia in Sudden Sensorineural Hearing Loss: SHIP Trial\nEstimated primary
  completion: June 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/insulin-aspart#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07652528
URL:https://assetmemo.bio/drug/insulin-aspart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
